Sanofi, Regeneron Expand Immunology Alliance With New Antibodies
Article excerpt
Sanofi SNY and Regeneron Pharmaceuticals REGN announced that they have expanded their existing longstanding antibody collaboration to include four next-generation, long-acting antibodies targeting type II inflammation. Per the expanded agreement, the companies will co-develop and co-commercialize four Regeneron-invented antibodies targeting interleukin-13 (IL-13), IL-4xIL-13 bispecific, interleukin-4 (IL-4) and interleukin-4 receptor alpha (IL-4Rα). One of the programs, REGN20423, is a long-acting IL-13 monoclonal antibody currently being evaluated in a phase I study for atopic dermatitis. The other three antibodies are expected to enter clinical studies in 2027. Regeneron will also have an option to include Sanofi's investigational candidate, lunsekimig, a bispecific nanobody therapy targeting TSLP and IL-13, in the latest collaboration after completion of its phase III studies in chronic obstructive pulmonary disease. REGN is entitled to receive an upfront payment of $1 billion from SNY. It is also eligible to receive up to $7 billion in additional development, regulatory and commercial milestone payments. Both companies will equally share development and commercialization costs and future profits from the potential products globally. Regeneron will lead research and development activities, while Sanofi will oversee global commercial efforts. Sanofi and Regeneron also...
Keep reading with a free account
The rest of this article, and every signal for Sanofi, is in your free account.
Extracted from this sentence
Dupixent generated sales of €9.3 billion in the first half of 2026, up 28.6% year over year.
